Takeda and Zinfandel begin Phase III trial of low dose pioglitazone

Takeda Pharmaceutical Company and partner, Zinfandel Pharmaceuticals, have begun Phase III trial, also known as TOMMORROW, to assess investigational low dose pioglitazone.

Source: Drug Development Technology - August 26, 2013 Category: Pharmaceuticals Source Type: news